Home › Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate
 

Keywords :   


Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate

2013-02-26 17:15:00| drugdiscoveryonline News Articles

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. recently announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323

Tags: agreement develop worldwide jazz

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Forecast Discussion Number 5
06.10Hurricane Kirk Graphics
06.10Tropical Storm Milton Wind Speed Probabilities Number 5
06.10Tropical Storm Milton Public Advisory Number 5
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Hurricane Kirk Forecast Discussion Number 29
06.10Hurricane Kirk Wind Speed Probabilities Number 29
More »